NLRP3 and acute myeloid leukemia: In acute myeloid leukemia (AML) with TP53 mutations, the therapeutic agent DNA methyltransferase inhibitors (DNMTis) expressed endogenous retroviruses (ERVs), IFNs and activated NLRP3 inflammasome in a STING-dependent manner [201].